posted on 2025-03-04, 07:18authored byZhaowei Zhang, Xuyang Liu, Chuanyue Peng, Rui Du, Xiaoqin Hong, Jia Xu, Jiaming Chen, Xiaomin Li, Yujing Tang, Yuwei Li, Yang Liu, Chen Xu, Dingbin Liu
Colorectal cancer (CRC) remains a formidable threat to
human health,
with considerable challenges persisting in its diagnosis, particularly
during the early stages of the malignancy. In this study, we elucidated
that fecal extracellular vesicle microRNA signatures (FEVOR) could
serve as potent noninvasive CRC biomarkers. FEVOR was first revealed
by miRNA sequencing, followed by the construction of a CRISPR/Cas13a-based
detection platform to interrogate FEVOR expression across a diverse
spectrum of clinical cohorts. Machine learning-driven models were
subsequently developed within the realms of CRC diagnostics, prognostics,
and early warning systems. In a cohort of 38 CRC patients, our diagnostic
model achieved an outstanding accuracy of 97.4% (37/38), successfully
identifying 37 of 38 CRC cases. This performance significantly outpaced
the diagnostic efficacy of two clinically established biomarkers,
CEA and CA19-9, which showed accuracies of mere 26.3% (10/38) and
7.9% (3/38), respectively. We also examined the expression levels
of FEVOR in several CRC patients both before and after surgery, as
well as in patients with colorectal adenomas (CA). Impressively, the
results showed that FEVOR could serve as a robust prognostic indicator
for CRC and a potential predictor for CA. This endeavor aimed to harness
the predictive power of FEVOR for enhancing the precision and efficacy
of CRC management paradigms. We envision that these findings will
propel both foundational and preclinical research on CRC, as well
as clinical studies.